Trial Profile
A Randomized, Double-Blind, Placebo Controlled Trial Examining the Safety and Efficacy of Midazolam Intranasal Spray (USL261) for the Treatment of Intermittent Bouts of Increased Seizure Activity in the Epilepsy Monitoring Unit (EMU)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 06 Nov 2020
Price :
$35
*
At a glance
- Drugs Midazolam (Primary)
- Indications Generalised seizures; Seizures
- Focus Registrational; Therapeutic Use
- Acronyms ARTEMIS EMU
- Sponsors UCB; Upsher-Smith
- 02 Nov 2020 Results published in the Epilepsia.
- 05 Dec 2017 Primary endpoint (Proportion of subjects that are seizure-free) has not been met as per the results presented at the 71st Annual Meeting of the American Epilepsy Society
- 05 Dec 2017 Results assessing safety and efficacy presented at the 71st Annual Meeting of the American Epilepsy Society